News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: FDA Affirms Superiority of Pradaxa® (dabigatran etexilate) 150 Mg Over Warfarin in Reduction of Both Ischaemic and Haemorrhagic Strokes



6/6/2012 10:05:20 AM

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim has today announced that it has updated the US prescribing information for Pradaxa® (dabigatran etexilate) in alignment with the US Food and Drug Administration (FDA) to affirm that “Pradaxa® 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin.”1 This positive change to the US label is based upon the results of the pivotal RE-LY® trial conducted in 18,000 patients with non-valvular atrial fibrillation, which demonstrated unequivocally the superior benefits offered by Pradaxa® in terms of effective prevention of stroke. In addition, RE-LY® demonstrated a significant benefit versus well controlled warfarin in life-threatening bleeding events, and major reductions in intracranial bleeding.2,3,‡

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES